Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Weight Management
Fat-metabolizing fragment of human growth hormone without growth-promoting effects.
Peptide B
Weight Management
Lilly's triple-agonist of GLP-1, GIP, and glucagon receptors — the strongest weight-loss data yet reported.
Typical vial
5 mg
Typical dose
250-500 mcg
Half-life
~30-60 minutes
FDA status
Not FDA approved as a drug. Granted GRAS status as a food ad…
Typical vial
10 mg
Typical dose
500-12000 mcg
Half-life
~6 days (~144 hours)
FDA status
Not FDA approved. In Phase 3 clinical trials (TRIUMPH progra…
AOD-9604 effects
Retatrutide effects
AOD-9604 side effects
Retatrutide side effects
AOD-9604 dosing ranges
Fat loss and body composition
250-500 mcg · Once daily (SubQ) · 8-12 weeks
Retatrutide dosing ranges
Obesity / weight loss (Phase 2 / 3 protocol)
1-12 mg · Once weekly (SubQ), dose-titrated · Long-term per clinical protocol
Self-experimentation (no clinical guidance)
0.5 mg start, titrate to tolerance · Once weekly · Long-term with careful titration
AOD-9604: Fat-metabolizing fragment of human growth hormone without growth-promoting effects. Typical dose 250-500 mcg. Retatrutide: Lilly's triple-agonist of GLP-1, GIP, and glucagon receptors — the strongest weight-loss data yet reported. Typical dose 500-12000 mcg. Both fall under the Weight Management category.
Stacking AOD-9604 with Retatrutide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
AOD-9604 is typically dosed: Once daily (SubQ) for Fat loss and body composition. Retatrutide is typically dosed: Once weekly (SubQ), dose-titrated for Obesity / weight loss (Phase 2 / 3 protocol); Once weekly for Self-experimentation (no clinical guidance).
AOD-9604: Not FDA approved as a drug. Granted GRAS status as a food additive in 2014. Retatrutide: Not FDA approved. In Phase 3 clinical trials (TRIUMPH program for obesity, SYNERGY-NASH for MASH). FDA submission anticipated 2026-2027 pending Phase 3 readouts.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free